Aptevo Therapeutics Inc Cash Flow Conversion Efficiency
Aptevo Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Aptevo Therapeutics Inc (APVO) has a cash flow conversion efficiency ratio of -0.903x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.45 Million) by net assets ($6.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aptevo Therapeutics Inc (2014–2025)
Cash flow conversion efficiency of Aptevo Therapeutics Inc from 2014 to 2025. This chart illustrates how Aptevo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Aptevo Therapeutics Inc (APVO) share price today for real-time trading data and today's change.
Aptevo Therapeutics Inc Cash Flow Conversion Ratio Explained
Aptevo Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aptevo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aptevo Therapeutics Inc ranked by their cash flow conversion efficiency. Also see APVO market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nuwellis Inc
NASDAQ:NUWE
|
1.553x |
|
SIGNATURE RESOURCES NEW
F:3S30
|
1.468x |
|
Global Power Solutions Corp.
V:PWER
|
0.240x |
|
NuGen Medical Devices Inc
V:NGMD
|
0.066x |
|
Lanesborough Real Estate Investment Trust
V:LRT-UN
|
0.011x |
|
ROUTE1 INC.
F:3R6N
|
-0.683x |
|
Nexera Energy Inc
V:NGY
|
-0.007x |
|
Appulse Corp
V:APL
|
0.003x |
Annual Cash Flow Conversion Efficiency for Aptevo Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Aptevo Therapeutics Inc from 2014 to 2025. Review APVO FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.38 Million | $-25.59 Million | -1.472x | +70.56% |
| 2024-12-31 | $4.75 Million | $-23.79 Million | -5.002x | -421.15% |
| 2023-12-31 | $12.22 Million | $-11.73 Million | -0.960x | +17.93% |
| 2022-12-31 | $17.97 Million | $-21.02 Million | -1.170x | +93.44% |
| 2021-12-31 | $1.22 Million | $-21.68 Million | -17.828x | -909.07% |
| 2020-12-31 | $16.59 Million | $-29.32 Million | -1.767x | +50.64% |
| 2019-12-31 | $11.84 Million | $-42.38 Million | -3.579x | -111.63% |
| 2018-12-31 | $30.41 Million | $-51.42 Million | -1.691x | -233.72% |
| 2017-12-31 | $82.03 Million | $-41.57 Million | -0.507x | +30.48% |
| 2016-12-31 | $50.57 Million | $-36.86 Million | -0.729x | -32.49% |
| 2015-12-31 | $88.62 Million | $-48.76 Million | -0.550x | -10.74% |
| 2014-12-31 | $94.61 Million | $-47.01 Million | -0.497x | -- |
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune … Read more